Domino to counsel Total visitors on implementation of serialisation schemes

Published: 3-Jun-2013
Regulatory

Ahead of Falsified Medicines Directive deadline


In anticipation of the impending Falsified Medicines Directive (FMD) deadline, Domino Printing Sciences’ Global Life Sciences Sector Manager Craig Stobie, is joining forces with Ian Haynes, Managing Director of 3C Integrity and formerly AstraZeneca’s Associate Engineering Director, at Total Processing and Packaging 2013 to help visitors implement serialisation schemes based on lessons learned from global pilot projects.

Speaking on Thursday 6 June between 12.00-12.45pm in the Interphex Theatre, Stobie and Haynes will share practical experience from an AstraZeneca serialisation pilot and highlight the key challenges and opportunities that arise when devising and implementing brand and patient protection projects.

Hosted by Lynn Bryan, ISPE UK Chair, the seminar will also update delegates on the latest global legislation and how the FMD will affect all areas of the sector – from engineering through to marketing and stakeholder engagement.

‘Domino is delighted to partner Ian for this presentation: having led a global serialisation project long before legislation mandated it, he is well versed in the challenge that serialisation brings to manufacturers, not just to engineering teams but also across the organisation,’ says Stobie.

‘The FMD in Europe and other legislation such as e-Pedigree in the US will see product security projects being implemented on a wide scale, but it is not an easy road. Total offers the perfect platform for us to meet pharmaceutical manufacturers and we are looking forward to sharing what we’ve learned.’

  • Companies:
  • Domino Printing Sciences
See more

You may also like

Manufacturing

Pharmaceutical serialisation – what’s coming down the line?

Read more
Bart Vansteenkiste (pictured), Global Life Sciences Sector Manager, Domino Printing Sciences, highlights the patient safety measures on the horizon

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. Innovating with purpose for safety and security of outcome Beyond the importance of increasing productivity and generating more output and value with the same input, new ideas and technologies from GEA take innovation a step further
  5. AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Pharmaceutical serialisation – what’s coming down the line?

Bart Vansteenkiste (pictured), Global Life Sciences Sector Manager, Domino Printing Sciences, highlights the patient safety measures on the horizon
Packaging

2D codes: preparing for the new dimension

After successful implementation in sectors including tobacco and pharmaceuticals, two-dimensional barcodes or 2D codes are gaining prevalence across industries and are expected at the point of sale within the next 5 years
Packaging

Countdown to CLP compliance: understanding the Unique Formula Identifier

From surface cleaner and thick bleach to insect killer and drain unblocker – there are thousands of everyday products on the market that contain chemicals that can be hazardous to human health if not handled correctly
Packaging

The EU MDR 2021: countdown to compliance

In April 2020, when the European Parliament voted to delay the implementation of the EU’s Medical Device Regulation by a year, some medical device manufacturers may have breathed a sigh of relief
Packaging

Printer validation packs: don’t leave compliance to chance

Validation impacts every process and component of pharmaceutical production, including machines, systems, equipment and computer systems, explains Bart Vansteenkiste from Domino Printing Sciences
Packaging

Five ways to achieve maximum efficiency in coding and marking

The Holy Grail of maximum coding and marking efficiency could be realised with Industry 4.0 automation, explains Adem Kulauzovic, Director of Coding Automation at Domino Printing Sciences
Packaging

The countdown to the Falsified Medicines Directive

The Falsified Medicines Directive (FMD) introduces harmonised measures to fight falsification, ensure that medicines are safe and that their identity can be authenticated within the EU member states. To what extent is this going to impact the pharmaceutical industry?
Subscribe now